Topical cocaine can treat ABMD

Article

Cocaine-assisted epithelial debridement is a simple and inexpensive treatment method for symptomatic anterior basement membrane dystrophy (ABMD) patients, reveals the latest study in the journal Cornea.

Cocaine-assisted epithelial debridement is a simple and inexpensive treatment method for symptomatic anterior basement membrane dystrophy (ABMD) patients, reveals the latest study in the journal Cornea.

Dr Rony R. Sayegh et al., Department of Ophthalmology and Visual Sciences, University of Maryland School of Medicine, Baltimore, Maryland, USA, conducted a retrospective chart review on 33 eyes of 27 symptomatic patients with ABMD who were treated with 4% topical cocaine followed by epithelial debridement.

The main outcome measures included preoperative and postoperative best-corrected visual acuities (BCVA), topography, subjective symptoms, complications and evidence of disease recurrence.

Recurrent erosion symptoms were present in 17 eyes of 14 patients (group 1) and 16 eyes of 13 patients (group 2) experienced reduced visual acuity from irregular astigmatism.

Group 1 presented with one patient who experienced symptomatic recurrence of the corneal erosion. In group 2 one patient experienced significant postoperative corneal haze. BCVA in group 1 improved from an average of 20/45 preoperatively to 20/38 at the last follow-up visit and 20/63 to 20/32 in group 2.

The treatment is ideal for ABMD patients who experience recurrent corneal erosions or irregular astigmatism, causing decreased visual acuity.

Please click here to read the study abstract.

Related Videos
Ana Neves, head of global marketing for ZEISS Meditec Ophthalmology
Fritz Hengerer, MD, PhD, Director, Eye Hospital at Bürgerhospital, Frankfurt, Germany
Dr Sheng Lim, professor of glaucoma studies at St Thomas' Hospital, London
Kasperi Kankare at the iCare booth at ESCRS
Scott D Barnes, MD, CMO of STAAR Surgical
Tomislav Bucalic, head of marketing at Geuder, and David Geuder, member of the executive board and CIO
Related Content
© 2023 MJH Life Sciences

All rights reserved.